@Article{096504020X15942028641011,
AUTHOR = {Lili Deng, Xue Yang, Jun Fan, Yuedi Ding, Ying Peng, Dong Xu, Biao Huang, Zhigang Hu},
TITLE = {IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects  via Multiple Pathways in Colorectal Cancer},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {6},
PAGES = {579--590},
URL = {http://www.techscience.com/or/v28n6/48496},
ISSN = {1555-3906},
ABSTRACT = {Colorectal cancer is an aggressive malignancy for which there are limited treatment options. Oncolytic vaccinia 
virus is being developed as a novel strategy for cancer therapy. Arming vaccinia virus with immunostimulatory 
cytokines can enhance the tumor cell-specific replication and antitumor efficacy. Interleukin-24 (IL-24) is an 
important immune mediator, as well as a broad-spectrum tumor suppressor. We constructed a targeted vaccinia 
virus of Guang9 strain harboring IL-24 (VG9-IL-24) to evaluate its antitumor effects. In vitro, VG9-IL-24 
induced an increased number of apoptotic cells and blocked colorectal cancer cells in the G<sub>2</sub>
/M phase of the 
cell cycle. VG9-IL-24 induced apoptosis in colorectal cancer cells via multiple apoptotic signaling pathways. 
In vivo, VG9-IL-24 significantly inhibited the tumor growth and prolonged the survival both in human and 
murine colorectal cancer models. In addition, VG9-IL-24 stimulated multiple antitumor immune responses and 
direct bystander antitumor activity. Our results indicate that VG9-IL-24 can inhibit the growth of colorectal 
cancer tumor by inducing oncolysis and apoptosis as well as stimulating the antitumor immune effects. These 
findings indicate that VG9-IL-24 may exert a potential therapeutic strategy for combating colorectal cancer.},
DOI = {10.3727/096504020X15942028641011}
}